Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide

In patients with metastatic castrate‐resistant prostate cancer (mCRPC), circulating tumor DNA (ctDNA) analysis offers novel opportunities for the development of non‐invasive biomarkers informative of treatment response with novel agents targeting the androgen‐receptor (AR) pathway, such as abiratero...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Cancer
Main Authors: Belic, Jelena, Graf, Ricarda, Bauernhofer, Thomas, Cherkas, Yauheniya, Ulz, Peter, Waldispuehl‐Geigl, Julie, Perakis, Samantha, Gormley, Michael, Patel, Jaymala, Li, Weimin, Geigl, Jochen B., Smirnov, Denis, Heitzer, Ellen, Gross, Mitchell, Speicher, Michael R.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Tumor Markers and Signatures
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6099279/
https://ncbi.nlm.nih.gov/pubmed/29574703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31397
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki